| __timestamp | Iovance Biotherapeutics, Inc. | Mesoblast Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 2704597 | 55305000 |
| Thursday, January 1, 2015 | 15470000 | 77593000 |
| Friday, January 1, 2016 | 28037000 | 50013000 |
| Sunday, January 1, 2017 | 71615000 | 58914000 |
| Monday, January 1, 2018 | 99828000 | 65927000 |
| Tuesday, January 1, 2019 | 166023000 | 59815000 |
| Wednesday, January 1, 2020 | 201727000 | 56188000 |
| Friday, January 1, 2021 | 259039000 | 53012000 |
| Saturday, January 1, 2022 | 294781000 | 32815000 |
| Sunday, January 1, 2023 | 344077000 | 27189000 |
| Monday, January 1, 2024 | 25353000 |
Unleashing the power of data
In the competitive world of biotechnology, innovation is the lifeblood of success. Over the past decade, Iovance Biotherapeutics, Inc. and Mesoblast Limited have been at the forefront of this race, each investing heavily in research and development (R&D) to pioneer groundbreaking therapies.
From 2014 to 2023, Iovance Biotherapeutics has consistently increased its R&D spending, culminating in a staggering 12,600% rise by 2023. In contrast, Mesoblast Limited's investment peaked in 2015 and has since seen a gradual decline, with a 64% reduction by 2023. This divergence highlights Iovance's aggressive push towards innovation, while Mesoblast appears to be adopting a more conservative approach.
The data suggests that Iovance's strategy may be positioning it as a leader in the biotech sector, while Mesoblast's cautious spending could reflect a focus on optimizing existing resources.
Research and Development Expenses Breakdown: Novo Nordisk A/S vs Mesoblast Limited
Who Prioritizes Innovation? R&D Spending Compared for Amgen Inc. and Iovance Biotherapeutics, Inc.
Intra-Cellular Therapies, Inc. or Mesoblast Limited: Who Invests More in Innovation?
Comparing Innovation Spending: Ascendis Pharma A/S and Mesoblast Limited
Grifols, S.A. or Iovance Biotherapeutics, Inc.: Who Invests More in Innovation?
Amneal Pharmaceuticals, Inc. or Mesoblast Limited: Who Invests More in Innovation?
Analyzing R&D Budgets: CRISPR Therapeutics AG vs Iovance Biotherapeutics, Inc.
Research and Development Expenses Breakdown: Bausch Health Companies Inc. vs Mesoblast Limited
R&D Spending Showdown: Catalyst Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Protagonist Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
R&D Spending Showdown: Mesoblast Limited vs Galapagos NV
R&D Insights: How Mesoblast Limited and Celldex Therapeutics, Inc. Allocate Funds